Prademagene Zamikeracel: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Prademagene Zamikeracel. Educational only — not medical advice.
Labeled uses
ZEVASKYN is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Source: FDA labeling via NIH DailyMed (set f8782480…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.